Novartis AG

Novartis International AG is a multinational pharmaceutical company based in Basel, Switzerland, ranking number three in sales among the world-wide industry.[when?] Company sales totalled 36.173 billon US$ in 2008. Currently,[when?] Novartis is the sixth largest pharmaceutical company in terms of revenue ($41.5 billion in 2009) with a profit margin of about 20%, which is the same as its industry competitors. Novartis profits were down by 31% from 2007 levels. Novartis manufactures such drugs as clozapine (Clozaril), diclofenac (Voltaren), carbamazepine (Tegretol), valsartan (Diovan), imatinib mesylate and (Gleevec / Glivec). Additional agents include ciclosporin (Neoral / Sandimmun), letrozole (Femara), methylphenidate (Ritalin), terbinafine (Lamisil), and others. Renamed to Novartis following an acquisition by Ciba-Geigy, it owns Sandoz, a large manufacturer of generic drugs. The company formerly owned the Gerber Products Company, a major infant and baby products producer, but sold it to Nestlé on 1 September 2007.

Source: Wikipedia

Campaign Finance

Information

Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:

  • contributions under $200 are not reported, and so are not included in totals.
  • only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
  • contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
  • corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
  • organization totals include known subsidiaries of the organization.

For more information, please see our campaign finance methodology page. Lobbyist bundling data is described on our lobbyist bundling methodology page.

Latest FEC Data

covers through committee's December 31, 2012 filing.
  • Summary

    overview of the committee's finances
    Total Raised:
    $713,785
    Total Spent:
    $644,312
    Cash on Hand:
    $202,800
    Debts:
    $0

Standardized Donation Information

covers roughly through Q4 2013. may lag behind FEC section above, as donors and industries are identified by hand.
  • Top Recipients

    PAC Color Block
    Organization's PAC(s)
    Employee Color Block
    Associated Individuals
    Includes contributions from the organization’s employees, their family members, and its political action committee.
  • Republicans vs. Democrats

    in dollars. "Other" includes 3rd parties and organizations without official party affiliation.
  • State vs. Federal

    in dollars
  • Top PAC Recipients

    PAC Color Block
    Organization's PAC(s)
    Employee Color Block
    Associated Individuals
    Includes contributions from the organization’s employees, their family members, and its political action committee.
View all campaign finance data for Novartis AG Sources: OpenSecrets.org FollowTheMoney.org

Lobbying

$14,106,136 Spent
Information

Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.

For more information, please see our lobbying methodology page.

covers roughly through Q4, 2013

Lobbying on Behalf of Novartis AG

  • Names of Lobbyists
  • Firm Hired Amount
    Novartis Corp $13,701,136
    Alcon Laboratories $823,000
  • Most Frequently Disclosed Lobbying Issues
    • Health Issues,
    • Fed Budget & Appropriations,
    • Medicare & Medicaid,
    • Taxes,
    • Trade,
    • Medical Research & Clin Labs,
    • Copyright, Patent & Trademark,
    • Government Issues,
    • Labor, Antitrust & Workplace,
    • Animals
  • Most Frequently Disclosed Bills
    Bill No. Title
    S.23 Patent Reform Act of 2011
    H.R.1 Full-Year Continuing Appropriations Act, 2011
    H.R.1548 Right to Rent Act of 2011
    S.1423 Preserving Access to Orphan Drugs Act of 2011
    H.R.276 To amend title 38, United States Code, to allow for the transfer of educational assistance under the Post-9/11 Educational Assistance Program to certain dependents to be used for special education.
    H.R.436 Protect Medical Innovation Act of 2011
    H.R.452 Medicare Decisions Accountability Act of 2011
    H.R.1458 Law Student Clinic Participation Act of 2011
    H.R.3590 Service Members Home Ownership Tax Act of 2009
    S.17 Medical Device Access and Innovation Protection Act
View all lobbying data for Novartis AG Sources: OpenSecrets.org

Regulations

Mentioned in 74 dockets; Submitted to 15 dockets
Information

All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.

Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.

Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.

Regulations and public comments can be downloaded in bulk here.

updated daily from Regulations.gov by way of Docket Wrench

The tables show occurrences of "Novartis AG" in public comments on proposed federal regulations.

Contractor Misconduct

2 Instances
Information

This information is collected by the Project On Government Oversight from press releases, court documents, news reports and other public records. It is not meant to be an exhaustive account of all instances of federal contractor misconduct.

More information on each instance, including primary source documents, is available on POGO's site by clicking on the instance description. More information on POGO's methodology is available here.

covers through POGO's March 5, 2013 release
Misconduct Type Hired By Incident Year Disposition Penalty
Labor None Nationwide Wage and Hour Class Action Lawsuit 2012 Settlement $99,170,000
Antitrust None Pharmaceutical Industry Average Wholesale Price Litigation 2011 Settlement $0
View all contractor misconduct data for Novartis AG Sources: Federal Contractor Misconduct Database from POGO